Ryan Watts, Denali CEO
August 6, 2020 08:42 AM EDTUpdated 02:14 PM
Deals

Bio­gen hands De­nali $1B-plus in cash, $1B-plus in mile­stones to part­ner on late-stage Parkin­son’s drug

John Carroll

Editor & Founder

Bio­gen is hand­ing over more than a bil­lion dol­lars cash to part­ner with the up-and-com­ing neu­ro­sciences crew at De­nali on a new ther­a­py for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times